OTCPK:MGFR.F

Stock Analysis Report

Executive Summary

MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland.

Snowflake

Fundamentals

Exceptional growth potential and good value.

Share Price & News

How has MagForce's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:MGFR.F

-0.9%

US Medical Equipment

1.3%

US Market


1 Year Return

n/a

OTCPK:MGFR.F

9.1%

US Medical Equipment

2.0%

US Market

No trading data on MGFR.F.

No trading data on MGFR.F.


Share holder returns

MGFR.FIndustryMarket
7 Day0%-0.9%1.3%
30 Day0%0.7%3.9%
90 Dayn/a4.4%3.4%
1 Yearn/a10.0%9.1%4.2%2.0%
3 Year2.0%2.0%70.7%65.5%47.2%37.6%
5 Year-44.2%-44.2%130.7%104.3%60.5%42.9%

Price Volatility Vs. Market

How volatile is MagForce's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is MagForce undervalued based on future cash flows and its price relative to the stock market?

45%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

MagForce's share price is below the future cash flow value, and at a moderate discount (> 20%).

MagForce's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

MagForce is good value based on earnings compared to the US Medical Equipment industry average.

MagForce is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

MagForce is good value based on expected growth next year.


Price Based on Value of Assets

MagForce is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is MagForce expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

57.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

MagForce's revenue is expected to grow significantly at over 20% yearly.

MagForce's earnings are expected to grow significantly at over 20% yearly.

MagForce's revenue growth is expected to exceed the United States of America market average.

MagForce's earnings growth is expected to exceed the United States of America market average.

MagForce's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

MagForce is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).


Next Steps

Past Performance

How has MagForce performed over the past 5 years?

-14.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

MagForce's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.

MagForce has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

MagForce has become profitable in the last year making it difficult to compare the US Medical Equipment industry average.


Return on Equity

MagForce has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

MagForce used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

It is difficult to establish if MagForce improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is MagForce's financial position?


Financial Position Analysis

MagForce is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

MagForce's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

MagForce's level of debt (87.4%) compared to net worth is high (greater than 40%).

Unable to establish if MagForce's debt level has increased without past 5-year debt data.

Unable to verify if debt is well covered by operating cash flow as MagForce has not reported sufficient balance sheet data.

Unable to confirm if the interest payments on MagForce's debt are well covered by earnings due to lack of past financial data.


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.2x debt.


Next Steps

Dividend

What is MagForce's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate MagForce's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate MagForce's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as MagForce has not reported any payouts.

Unable to verify if MagForce's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as MagForce has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of MagForce's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of MagForce's salary, the management and board of directors tenure and is there insider trading?

6.9yrs

Average management tenure


CEO

Ben Lipps (79yo)

6yrs

Tenure

0

Dr. Benjamin J. Lipps, also known as Ben, has been the Chairman of the Management Board and Chief Executive Officer at MagForce AG since September 1, 2013. Dr. Lipps served as the Chief Executive Officer a ...


Management Age and Tenure

6.9yrs

Average Tenure

62yo

Average Age

The average tenure for the MagForce management team is over 5 years, this suggests they are a seasoned and experienced team.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Andreas Jordan (60yo)

    Founder & Advisor

    • Tenure: 0yrs
  • Ben Lipps (79yo)

    Chairman of the Management Board & CEO

    • Tenure: 6yrs
  • Christian Von Volkmann (48yo)

    CFO & Member of Management Board

    • Tenure: 6.9yrs
  • Hans Hutt

    Medical Consultant

    • Tenure: 8.8yrs
  • Solveig Salomon

    VP of Marketing & Sales and European Commercial Director

    • Tenure: 0yrs
  • Barbara Frankenberg

    Vice President of Communications & Investor Relations

    • Tenure: 3.5yrs
  • Hoda Tawfik (64yo)

    Chief Medical Officer & Member of Management Board

    • Tenure: 6.9yrs

Board Members

  • Norbert Neef (52yo)

    Chairman of the Supervisory Board

    • Tenure: 0yrs
  • Wiebke Rösler

    Member of the Supervisory Board

    • Tenure: 5.1yrs
  • Klemens Hallmann (43yo)

    Deputy Chairman of Supervisory Board

    • Tenure: 2.1yrs

Company Information

MagForce AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MagForce AG
  • Ticker: MGFR.F
  • Exchange: OTCPK
  • Founded: 1997
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €124.934m
  • Listing Market Cap: €138.354m
  • Shares outstanding: 27.64m
  • Website: https://www.magforce.com

Number of Employees


Location

  • MagForce AG
  • Max-Planck-Strasse 3
  • Berlin
  • Berlin
  • 12489
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MF6DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2007
MF6XTRA (XETRA Trading Platform)YesCommon StockDEEURSep 2007
MGFR.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDSep 2007
0W10LSE (London Stock Exchange)YesCommon StockGBEURSep 2007

Biography

MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland. It offers NanoTherm therapy for the treatment of solid tumors; NanoTherm, a ferrofluid liquid containing su ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:11
End of Day Share Price2019/06/26 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.